Javier Perez, MD
Glaucoma Specialist · Orlando, FLNPI 1609855089
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,442 of the $5,015 with a category attached, or 88.6%. 21 manufacturers reported payments, led by Alcon at 25.7% of the total.
Across 122 payments — averaging $41.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- NEW World Medical,inc.$603
- Sight Sciences, Inc.$366
- Bausch & Lomb Americas Inc.$313
- Ocular Therapeutix, Inc.$249
- plus $1K from 15 others
What the payments were for
- Travel & lodging$55511%
- Food & beverage$4,44289%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 32 | $1,287 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $1,073 |
| NEW World Medical,inc. | 10 | $603 |
| Sight Sciences, Inc. | 16 | $366 |
| Bausch & Lomb Americas Inc. | 12 | $313 |
| Ocular Therapeutix, Inc. | 3 | $249 |
| AbbVie(2 entities) | 8 | $231 |
| Kala Pharmaceuticals, Inc. | 5 | $203 |
| Sun Pharmaceutical Industries Inc. | 7 | $150 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Aerie Pharmaceuticals, Inc. | 6 | $118 |
| Rayner Intraocular Lenses Limited | 3 | $60 |
| Novartis | 2 | $47 |
| Harrow Eye, LLC | 2 | $47 |
| Tarsus Pharmaceuticals, Inc. | 1 | $37 |
| Amgen | 1 | $21 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $18 |
| Glaukos Corporation | 1 | $17 |
| Rxsight Inc | 1 | $17 |
| Dompe US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$849
- Tecnis 3-piece IOL$849
- Tecnis Symphony IOL$849
- Tecnis Symphony Toric IOL$849
- Ahmed Glaucoma Valve$438
- Kahook Dual Blade$438
- Clareon$322
- Clareon PanOptix Pro$266
- Clearpath$264
- Streamline$264
- Unity$148
- EYLEA HD$125
- Via360$120
- INVELTYS$110
- DEXTENZA$100
How this compares
$5,015 in reported general payments places this provider in the 60th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 95 | $52,786 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $31,445 |
| RestasisCyclosporine | 19 | $26,311 |
| VyzultaLatanoprostene Bunod | 57 | $22,591 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $14,229 |
| Timolol Maleate | 508 | $13,435 |
| Latanoprost | 868 | $12,476 |
| RhopressaNetarsudil Mesylate | 29 | $11,996 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 37 | $10,980 |
| Brinzolamide | 46 | $10,157 |
| XiidraLifitegrast | 11 | $8,989 |
| Prednisolone Acetate | 160 | $8,897 |
| Alphagan PBrimonidine Tartrate | 26 | $7,272 |
| Bromfenac Sodium | 65 | $7,146 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 345 | $6,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $231 | $117,815205 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $313 | $31,57968 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $118 | $26,22547 claims |
| AlconSimbrinza | $1,287 | $10,98037 claims |
| NovartisIlevro | $47 | $6,34717 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $18 | $3,24118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Orlando
- Analisa ArosemenaMiami Beach$438K
- Steven VoldWinter Garden$413K
- Matthew BrinkPalm Beach Gardens$159K
- David GreenfieldMiami$32K
- Mark WernerDelray Beach$24K
- Dan ArreazaHialeah$9K
- Daniel JewelewiczDelray Beach$9K
- Joah AliancyPort Orange$7K
- Phil AlabataCrestview$7K
- Clinton SheetsHudson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.